Latest releases

Aug 5, 2020 ı Corporate Releases

Lundbeck discontinues phase II proof of concept study of Lu AF11167 in patients with negative symptoms of schizophrenia

Jun 9, 2020 ı Press Releases

Lundbeck plans to refocus and reinvigorate Research & Development

View all releases

Q2 2020 results

Teleconference
Date: August 13, 2020
Time: 13.00 pm CET / 07.00 am ET
Webcast
Dial ins:
DK: +45 78150107
UK: +44 3333009032
US: +1 6467224957

Latest feature

July 2020: 

 

Finding the cure for Parkinson’s disease with camel nanobodies

 

Read more

 

Go to all features

Join Lundbeck

Current open positions

Browse global vacancies

The Lundbeck Magazine

The Lundbeck Magazine portrays true patient stories to reduce the stigma surrounding people with brain diseases.

 

Read the latest edition

Share price

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.